CERAMENT™|G - Bone Healing and Re-infection Prophylaxis

Osteomyelitis Clinical Trial

Official title:

CERAMENT™|G - Bone Healing and Re-infection Prophylaxis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02128256
• Other study ID #: CeramentG-CH-2014
• Status: Recruiting
• Phase: Phase 4
• First received: April 23, 2014
• Last updated: December 1, 2015
• Start date: May 2014
• Est. completion date: May 2017

Study information

• Verified date: December 2015
• Source: University of Lausanne Hospitals
• Contact: Olivier Borens, MD
• Phone: 00 41 21 314 27 89
• Email: olivier.borens[@]chuv.ch
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

The surgical management of long bone infections is often challenging. Adequate surgical debridement decreases the bacterial load, removes dead tissues, and gives a chance for the host immune system and antibiotics to arrest infection. Adequate debridement may leave a large bony defect. An appropriate management of the dead space is essential to arrest the disease, and for maintenance of the bone's integrity. The current strategy includes the use of antibiotic-loaded bone cement that can be used to sterilize and temporarily maintain the dead space. The cement are usually removed after 2 to 4 weeks and replaced with a cancellous graft harvested from the hip of the patient.

CERAMENT™| G is a CE-marked resorbable ceramic bone graft substitute composed by calcium sulfate and calcium hydroxyapatite, intended to fill gaps and voids in the skeleton system and to promote bone healing. The antibiotic gentamicin is included in the ceramic to prevent colonization of gentamicin-sensible microorganisms in order to protect bone healing.

The aim of this study is to investigate the device absorption and bone in-growth of CERAMENT™| G in a surgically revised bone infection. In addition, bone healing and infection non-recurrence will be evaluated during 12 months of follow-up. The investigators expect a treatment success of >90 % and that a similar bone healing will be obtained as with a standard two-stage surgical procedure. In addition, the investigators believe that the use of CERAMENT™| G will be of advantage for the patient as bone healing will be achieved with a one-stage surgical procedure (in combination with antibiotic therapy), instead of a two-stage procedure, thus decreasing potential surgery-related complications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: May 2017
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients with a long bone infection in femur, tibia, humerus or radius

• Candidate for one stage procedure

• Patients above the age of 18

• Written informed consent obtained before any study-related activities

• Patients with communicative ability to understand the procedure and participate in the study and comply with the follow up program

Exclusion Criteria:

• Clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation

• Hypersensitivity to aminoglycoside antibiotics

• Myasthenia gravis

• Severe renal impairment

• Pre existing calcium metabolism disorder.

• Women who are pregnant or breastfeeding (a pregnancy test will be done in women of childbearing potential)

• History of hypersensitivity to the investigational device or any of its ingredients

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteomyelitis

Intervention

Device:
• Cerament G

Locations

Country	Name	City	State
Switzerland	Lausanne University Hospital, Service of Orthopedy and Traumatology	Lausanne	Vaud

Sponsors (1)

Lead Sponsor	Collaborator
Dr. Olivier Borens

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Degree of device absorption after insertion of the device (during follow-up).	The degree of device absorption will be evaluated by localized CT-scans 3 and 12 months after surgery.	3 and 12 months after surgery.	No
Primary	Advances in bone in-growth after insertion of the device (during follow up).	Bone in-growth will be evaluated by localized CT-scans 3 and 12 months after surgery.	3 and 12 months after surgery.	No
Secondary	Bone healing	Bone healing will be evaluated by X-ray 6 weeks, 3 months, 6 months and 12 months after surgery.	6 weeks, 3 months, 6 months and 12 months after surgery.	No
Secondary	Infection non-recurrence	Infection non-recurrence will be verified by measuring inflammatory blood parameters and body temperature, and through clinical examination (looking for pain, swelling, warmth and redness) during hospitalization (an expected average of 14 days following the surgery), and 6 weeks, 3 months, 6 months and 12 months after surgery (i.e. at each follow-up visit according to standard clinical praxis).	During hospitalisation and 6 weeks, 3 months, 6 months and 12 months after surgery.	No
Secondary	Serum gentamicin levels	For evaluation of the gentamicin elution from the ceramic, serum gentamicin levels will be measured 24 h, 48 h and 72 h after surgery (during hospitalisation).	24 h, 48 h and 72 h after surgery.	Yes